Pemphigus vulgaris is a rare, life-threatening autoimmune disorder characterized by blistering of the skin and mucous membranes. According to Corey Stone et al., 2024, its worldwide incidence ranges from 0.1 to 0.5 per 100,000 population, with prevalence varying across ethnic groups. Current therapies include corticosteroids, immunosuppressants, and emerging biologics. The growing focus on targeted therapies, such as monoclonal antibodies and FcRn antagonists, is shaping the treatment landscape. According to the pemphigus vulgaris pipeline analysis by Expert Market Research, ongoing clinical developments and increasing awareness of autoimmune diseases are expected to undergo significant growth in the coming years.
Major companies involved in the pemphigus vulgaris pipeline analysis include IRIS Research and Development, LLC, Artiva Biotherapeutics, Inc., and others.
Leading drugs currently in the pipeline include CM313, AB-101, DSG3-CAART or CABA-201, and others.
The pipeline is expanding with several novel biologics and targeted therapies in development. Increased clinical trials and strategic collaborations are expected to drive significant pipeline growth in the coming years.
The Pemphigus Vulgaris Pipeline Analysis Report by Expert Market Research gives comprehensive insights into pemphigus vulgaris therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pemphigus vulgaris. The pemphigus vulgaris report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pemphigus vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pemphigus vulgaris treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pemphigus vulgaris.
Read more about this report - Request a Free Sample
Pemphigus Vulgaris is a rare, potentially life-threatening autoimmune disorder characterized by painful blisters and erosions on the skin and mucous membranes. It occurs when the immune system produces autoantibodies against desmogleins 1 and 3, disrupting cell adhesion and causing intraepidermal blistering. Genetic predisposition, abnormal T cell activity, and autoimmune comorbidities contribute to disease development.
Pemphigus vulgaris treatment primarily involves corticosteroids combined with immunosuppressants. Rituximab, an anti-CD20 monoclonal antibody, is frequently used to deplete B cells, reduce autoantibody production, and induce disease remission. In the market, Rituximab continues to advance in the drug pipeline as of November 2022, with lower-dose regimens showing promising efficacy, improved patient tolerability, and reduced treatment costs while maintaining disease remission in early-stage patients.
According to Corey Stone et al., 2024, pemphigus vulgaris shows varied prevalence across ethnic groups, with a global incidence of 0.1-0.5 per 100,000 population. Incidence rates range from 0.76 new cases per million per year in Finland to 16.1 per million in Israel, linked to HLA class II genes, including HLA-DRB104 and HLA-A10, and the ST18 genomic segment. Onset typically occurs between the fourth and sixth decades, affecting men and women equally.
This section of the report covers the analysis of pemphigus vulgaris drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The pemphigus vulgaris pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, at 75%, covers a major share of the total pemphigus vulgaris clinical trials. It is followed by phase II with 25%. The strong presence in early clinical stages indicates a promising pipeline, suggesting potential for innovative therapies, increased treatment options, and growth in the pemphigus vulgaris treatment market.
The drug molecule categories covered under the pemphigus vulgaris pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The pemphigus vulgaris report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pemphigus vulgaris. Cell and gene therapies are emerging as a promising drug class in the pemphigus vulgaris treatment. For instance, resecabtagene autoleucel (rese-cel) is under evaluation in the RESET-PV trial, focusing on immunosuppressant-free treatment. It is designed to target autoreactive B cells and provide long-lasting clinical responses. Early data indicate favorable safety, with minimal cytokine release syndrome and no neurotoxicity observed in initial patients.
The EMR report for the pemphigus vulgaris pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed pemphigus vulgaris therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in pemphigus vulgaris clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pemphigus vulgaris. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pemphigus vulgaris drug candidates.
CM313, a novel humanized monoclonal antibody targeting CD38, is being developed to treat pemphigus vulgaris. Sponsored by Chao Ji from the First Affiliated Hospital of Fujian Medical University, this Phase 1/2 study is examining the safety, tolerability, and preliminary efficacy of CM313 in modulating B-cell activity. By binding to CD38 on B cells, CM313 is reducing autoantibody production responsible for blister formation. The study has enrolled 100 patients and is expected to start in October 2025, aiming to provide a targeted therapeutic approach for pemphigus.
AB-101 is an allogeneic, non-genetically modified natural killer (NK) cell therapy, currently being evaluated in combination with Rituximab for B-cell associated autoimmune diseases, including pemphigus vulgaris. Sponsored by IRIS Research and Development, LLC, this Phase 1 open-label study is examining the safety and efficacy of the combination, focusing on enhancing immune-mediated disease control. AB-101 works by boosting NK cell activity, offering targeted immunotherapy while potentially improving clinical outcomes in patients resistant to standard therapies.
DSG3-CAART is an investigational autologous CAR T-cell therapy being developed by Cabaletta Bio for treating active pemphigus vulgaris (PV). This Phase 1/2, open-label study is examining the safety, tolerability, and optimal dosing schedule of DSG3-CAART in patients with mucosal PV inadequately managed by standard therapies. The study is also evaluating CABA-201, a CD19-specific CAR T-cell therapy, to determine if it can achieve clinical responses safely without preconditioning. Both therapies aim to induce durable remission by targeting B-cell-mediated autoimmunity.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Pemphigus Vulgaris Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for pemphigus vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pemphigus vulgaris collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share